Publications by authors named "Barbara Gitlitz"

Claim this Profile
B
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
Solange Peters, Christian Schulz, Martin Reck, Kumar Prabhash, Dariusz Kowalski, Barbara Gitlitz

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
Enriqueta Felip, Heather A Wakelee, Chenqi Fu, Yu Deng, Fanny Masson, Barbara Gitlitz

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.
Baohui Han, Solange Peters, Anh Tuan Le, Dingzhi Huang, Gang Wu, Barbara Gitlitz

Chin Med J (Engl)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis.
Jay M Lee, Alessandro Brunelli, Amy L Cummings, Enriqueta Felip, Catherine A Shu, Barbara J Gitlitz

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Eric Vallières, Tibor Csoszi, Barbara J Gitlitz

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study).
Siow Ming Lee, Christian Schulz, Anne-Marie Baird, Kumar Prabhash, Dariusz Kowalski, Barbara Gitlitz

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
Alexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, Vinay Duddalwar, Kevin George King

Oncotarget· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Caicun Zhou, Minu K Srivastava, Hao Xu, Enriqueta Felip, Heather Wakelee, Barbara Gitlitz

J Immunother Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
Jay M Lee, Eric Vallières, Beiying Ding, Ann Johnson, Jan Bhagwakar, Barbara J Gitlitz

J Thorac Cardiovasc Surg· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon.
Jessica S Donington, Barbara Gitlitz, Eric Lim, Isabelle Opitz, Young Tae Kim

Ann Thorac Surg· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
Anjali Saqi, Kevin O Leslie, Andre L Moreira, Sylvie Lantuejoul, Catherine Ann Shu, Barbara J Gitlitz

JTO Clin Res Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Barbara Gitlitz

Lancet· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC.
Jay M Lee, Anthony W Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Barbara J Gitlitz

JTO Clin Res Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
Barbara J Gitlitz, Silvia Novello, Tiziana Vavalà, Marisa Bittoni, Alicia Sable-Hunt

JTO Clin Res Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ()-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
Karen L Reckamp, Paul H Frankel, Nora Ruel, Philip C Mack, Barbara J Gitlitz

Front Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Robert L Ferris, Nabil F Saba, Barbara J Gitlitz, Robert Haddad, Ammar Sukari

JAMA Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
Stephen V Liu, Susan G Groshen, Karen Kelly, Karen L Reckamp, Chandra Belani, Barbara J Gitlitz

Cancer Chemother Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Leora Horn, Jeffrey R Infante, Karen L Reckamp, George R Blumenschein, Ticiana A Leal, Barbara J Gitlitz

Clin Cancer Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, Edwin P Hui, Kwok-Wai Lo, Barbara J Gitlitz

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.
Ivan Vannini, Petra M Wise, Kishore B Challagundla, Meropi Plousiou, Mirco Raffini, Barbara J Gitlitz

Nat Commun· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.
Ivan Vannini, Petra M Wise, Kishore B Challagundla, Meropi Plousiou, Mirco Raffini, Barbara J Gitlitz

Nat Commun· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, Maria Y Fernandez-Rocha, Dean Pavlick, Barbara J Gitlitz

Lung Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Sai-Hong Ignatius Ou, Alexa B Schrock, Eduard V Bocharov, Samuel J Klempner, Carolina Kawamura Haddad, Barbara J Gitlitz

J Thorac Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Kartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, Francis J Giles, Barbara J Gitlitz

Cancer Discov· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.
Primo N Lara, James Moon, Mary W Redman, Thomas J Semrad, Karen Kelly, Barbara Gitlitz

Clin Lung Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis